Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
Code effective Dec 13, 2024
HCPCS Section
Medical services
M0244 is a valid 2026 HCPCS code meaning Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency or (Casirivi and imdevi inj hm) for short. HCPCS M0244 has been effective since 12/13/2024 and applies to Pneumococcal/flu vaccine.
|
HCPCS Level II Code Section M - Medical services |
|
| HCPCS Code | M0244 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
54 - Vaccinations
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| BETOS2 code | O1G - Immunizations/Vaccinations |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | V - Pneumococcal/flu vaccine |
| Effective date | Effective Dec 13, 2024 |
| Date added | Added May 06, 2021 |
| Termination date | Dec 12, 2024 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.